Several anti-angiogenic agents targeting the VEGF signaling pathway, including the anti-VEGF antibody bevacizumab (Avastin®, Genentech, South San Francisco, CA, USA) and tyrosine kinase inhibitors sorafenib (Nexavar®, Bayer, Leverkusen, Germany) and sunitinib (Sutent®, Pfizer, New York, NY, USA), have been approved for cancer treatment [5]. This evidence concerns the gene VEGFA and cancer.